top of page

๐„๐ฑ๐œ๐ข๐ญ๐ข๐ง๐  ๐ˆ๐ง๐ฏ๐ž๐ฌ๐ญ๐ฆ๐ž๐ง๐ญ ๐‘๐จ๐ฎ๐ง๐๐ฌ

๐„๐ฑ๐œ๐ข๐ญ๐ข๐ง๐  ๐ˆ๐ง๐ฏ๐ž๐ฌ๐ญ๐ฆ๐ž๐ง๐ญ ๐‘๐จ๐ฎ๐ง๐๐ฌ

  • AI SaaS startup on Monday said it hasย raised $2.5 millionย in its seed round led by US-based investors SVQuad and Inventus Capitalย to strengthen its equity research platform

  • Co-Founded by IIT-BHU graduates Deepak Sharmaย andย Ankit Varmani

  • aims to empower equity research analysts working in hedge funds, mutual funds andย investment banks.

  • ArtBlood is aย South Korean companyย producing BioBlood, an alternative solution to blood shortage issues

  • ArtBlood, founded byย Prof. Baek Eun Jung of Hanyang University's School of Medicine,ย is a startup with expertise in extracorporeal blood production.

  • South Korean bio startup ArtBlood, specializing in blood production for transfusion,ย announced on Tuesday that it successfully secured anย investment of 6.5 billion won ($4.8 million).

  • Healthtech startupย Butterfly Learnings raises Rs 32 crore from Insitor, Enzia Ventures, CIIE, others

  • Founded in 2021 by Sonam Kothari and Abhishek Sen, Butterfly Learnings provides individualized therapy regimens andย comprehensiveย support for children and families facing challenges related to neurodiversity

  • EyeMyEye, the full-stack eyewear platform, has successfully secured Rs 20.8 crore (approximately $2.5 million)ย in a new tranche as part of its pre-Series A round.

  • EyeMyEye intends to utilize these funds for operational purposes, achieving pre-defined milestones, and as outlined in the shareholderโ€™s agreement, states the filing

  • Gemeente Rotterdam-based Pryme, a chemical plastic recycling company, announced that it has secured โ‚ฌ10M in a fresh funding round from Taranis Investment Limited through its Taranis Carbon Ventures fund

  • Christopher Hervรฉ, CEO of Pryme

  • The companyโ€™s mission is to contribute to a circular plastic economy with a low carbon footprint.ย ย 

0 views0 comments


bottom of page